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Abstract
Harnessing the immune system and preventing immune escape, the immunotherapy of cancer provides great
potential for clinical application, in broad patient populations, achieving both conventional and unconventional clinical
responses. After the substantial advances in melanoma, the focus of cancer immunotherapy has expanded to include
many other cancers. Targeting immune checkpoints and further mechanisms used by tumors to avoid anticancer
immunity, different approaches are under evaluation, including combination therapies.
The first Immunotherapy Bridge meeting focused on various cancer types including melanoma, non-small cell lung
cancer, renal cell, breast and ovarian carcinoma, and discussed mechanisms of action of single agents and combination
strategies, and the prediction of clinical responses.
Introduction
The potential of immunotherapy to improve clinical out-
come in various solid and haematologic malignancies is
based on the ability of the immune system to exhibit
both innate (i.e., myeloid and lymphoid cells exerting a
rapid effector function) and adaptive responses (driven
by T- and B-lymphocytes expressing antigen receptors
produced by site-specific somatic recombination and
endowed with greater specificity retaining antigen mem-
ory) [1]. The approval of sipuleucel-T for the treatment
of prostate cancer was the first immuno-therapy to be
approved, followed by the approval of ipilimumab (anti-
CTLA-4), for the treatment of metastatic melanoma
and, later, of the anti PD-1 antibodies nivolumab (in
melanoma, non-small cell lung cancer, NSCLC, kidney
cancer, head & neck cancer), pembrolizumab (in melan-
oma, NSCLC and Head & Neck cancer), and talimogene
laherparepvec (T-VEC) in melanoma (the first oncolytic
viral therapy approved for treatment).
The clinical practice with checkpoint inhibition and
pathways activation has highlighted a number of important
considerations. Firstly, immunotherapy agents may be as-
sociated with patterns of response that differ from those
seen with other treatment modalities (i.e., chemotherapy)
and so their use may require the development of different
response criteria [2]. A response to anti-CTLA-4 or anti-
PD-1 may be observed after an initial increase in tumor
volume and a reduction in tumor burden may be observed
after the appearance of new lesions. These observations
suggest that treatment should be continued regardless of
an increase in volume of existing lesions or the early ap-
pearance of new lesions. Even more remarkable, durable
responses was observed even after cessation of treatment,
suggesting an ability of immunotherapy to reset the equi-
librium between host and tumor [3]. As an example, it is
now accepted that ipilimumab therapy in advanced mel-
anoma presents a plateau in the survival curve, beginning
at approximately 3 years [4]. Nevertheless, current criteria
(e.g., RECIST) might not be appropriate to asses these
types of responses. Another important consideration is that
immunotherapies can act regardless of patient characteristics
and tumor characteristics [5, 6]. Various approaches to
identify potential biomarkers for immunotherapies are
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being evaluated. A promising area of research is the use of
various immunotherapies in combination with one an-
other and/or with chemotherapy, targeted agents or
radiation.
Cancer vaccines revisited
Using a vaccination with CpG 7909 (PF 676), a 23-bp
oligodeoxynucleotide TLR-9 agonists, and a human
Melan-A peptide antigen (analogue, ELAGIGILTV)
emulsified in IFA (Incomplete Freund’s adjuvant), rapid
and efficient T cell responses were found in all vacci-
nated metastatic melanoma patients, with a frequency
10-fold higher than those vaccinated without CpG. The-
peak response was 7 to 11 days after booster injection.
Furthermore, effector memory (and central) T cells
expressing perforin, granzyme B, IFNγ and also CD28-
effector cells were generated. Finally, the killing of mel-
anoma cells and IFNγ secretion were observed [7, 8].
More recently robust and sustained CD4 and CD8 T cell
responses were found to be induced by vaccination with
the long synthetic NY-ESO79–108 peptide, CpG and IFA
(Baumgaertner P: Vaccination of melanoma patients
with long NY-ESO-1 peptide and CpG-B elicits robust
T-cell responses with multiple specificities and a novel
DR-7-restricted epitope, Submitted). Of the three
polypeptide-based cancer vaccines in advanced clinical
testing of a recombinant fusion nearly full length
MAGE-A3 protein, failed the first primary endpoint in
both lung cancer and melanoma, while HPV-16 long
synthetic peptides (LSPs) obtained 50 % complete re-
sponses in premalignant lesions, but no impact on over-
all survival (OS) was found in cervical carcinoma [9],
and, finally, IMA 109 (a mix of 9 short naturally pre-
sented peptides) followed a similar pattern as a clinical
efficacy signal was detected in a randomized phase II
clinical trial in renal cell carcinoma [10], but failed the
primary efficacy endpoint in the phase III trial. Hurdles
in vaccination with polypeptides include, first of all, rela-
tively weak T cell responses (narrow focused and short
lived), then inadequate induction of CD8 T cells by LSPs
and recombinant proteins (cross priming), and, finally,
local immunosuppression. Polypeptide-based vaccines
still need to be optimized, however they already showed
that (1) LSP (and proteins) depend on cross-
presentation for vaccination, (2) that XCL-1 may be used
as vaccine component to target antigen to XDCs and (3)
that fusion XCL-1 proteins are interesting candidates to
achieve consistently strong CD8 T cell responses and
protective immunity. Also, combination with nanoparti-
cle delivery is a promising approach. Regarding the
translation into clinic, toll-like receptor (TLR) agonists
as polypeptide vaccine adjuvants CpG-ODNs and
Poly(I:C) have been shown to dramatically increase the
antigen-specific effector T cell (Teff ):Treg ratio in the
lymphoid organs, skewing immune response in favor of
a functional anti-tumor effect. In addition, CpG-ODNs
and Poly(I:C) rapidly induce a Th1 polarized cytokine mi-
lieu, which fits with a reported mechanism for the adjuvant
activity of TLR ligands [11]. On the other hand, HER-2-
CD1d or CEA-CD1d fusion proteins efficiently function
both as vaccine adjuvants and driving Th1 shifts in the
tumor microenvironment, partly through transactivation of
NK cells, thus harnessing NKT for vaccination [12].
Unlike viral antigen specific T cell responses, molecularly
defined subunit vaccines (antigen and adjuvants) may not
efficiently induce long lived memory cells. Yet, robust
tumor antigen-specific T cell memory responses are needed
to sustain durable tumor responses. A deep understanding
of the signals involved in instructing T cell memory differ-
entiation should provide clues for the identification of com-
pounds that, added to subunit vaccines, may modulate the
quantity and quality of memory T cells. In this regard, in-
hibition of mTOR signaling by administration of rapamycin
during the expansion phase of a primary anti-viral CD8 T
cell response augments the size of the memory T cell pool
during the contraction phase [13]. The mTOR signaling
branches into two major complexes, mTORC1 and
mTORC2. Conditional genetic inactivation of mTORC1 in
T cells leads to a profound reduction of the primary CD8 T
cell response affecting the generation of both effector and
memory T cells. In marked contrast, the conditional dele-
tion of a functional mTORC2 complex leads to decreased
differentiation of short lived effector cells and a correspond-
ing increase in the formation of memory effector precursor
cells. This translates into enhanced recall responses to re-
challenge with antigen [14]. This observation provides the
rationale to dissect the signaling events downstream of
mTORC2 leading to instruction of memory T cell differ-
entiation. Nuclear accumulation of the transcription factor
FOXO1 is one of the key events. Future research should
reveal the specific transcriptional reprogramming events
controlled by FOXO1 which lead to memory formation.
Similar signaling events may operate in human CD8 T
cells [15].
Antigen-specific T cells, MDSCs and survival in melanoma
and breast cancer
Monitoring the immune status of cancer patients using per-
ipheral blood assays has several advantages over tumor-
infiltrating cells, such as being minimally invasive, repeat-
able ad libitum, usable to generate functional as well as
phenotypic data. The over-riding caveat is that, like any bio-
marker, it is only relevant if robustly associated with clinical
outcome. In a phase II study of a 10-peptide GM-CSF-
adjuvant vaccine in renal cell cancer (RCC) with or without
the addition of single low-dose cyclophosphamide, Walter
and colleagues showed that a T cell response to 3 or more
vaccine peptides was indicative of 100 % survival [10].
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Observed reductions of peripheral Tregs with a single dose
of cyclophosphamide suggests that suppressive cells might
be involved in the response to cancer antigens in these pa-
tients. Also, the relative abundance of cells with the pheno-
type CD14 +HLA-DRlow/negative influenced survival in the
RCC [10]. Stage IV melanoma patients, on the other hand,
possessed higher frequencies of circulating CD4+ Tregs
relative to healthy controls, but there was no correlation
with survival [16]. In the same study, it was found that the
frequencies of CD14 +CD11b +HLA-DR−/low monocytic
myeloid-derived suppressor cells (MDSCs) were higher in
patients compared to controls and that their levels did cor-
relate negatively with survival. The potential for enhancing
the strength of this correlation of MDSC with survival by
defining this cell type more accurately was investigated in a
pilot study using 45-channel mass spectrometry flow cy-
tometry (CyTOF) on cells preselected for being CD3-,
CD19-, CD11b+, CD14+ and CD45+. Comprehensive im-
mune signatures including MDSCs were found in patients
relative to controls, which correlated more closely with sur-
vival (Wistuba-Hamprecht et al. under revision).
Importantly, the in vitro reactivity of peripheral T cells
to tumor-associated antigens (TAA) such as NY-ESO-1
in patients with melanoma with distant metastases is
positively associated with a survival benefit [17]. Indicat-
ing the complexity of peripheral immune signatures and
their correlations with survival, CD8+ T cell reactivity to
Melan-A was also associated with survival, but only in
the absence of a response of CD4+ T cells producing IL
4 or IL 17 on stimulation with this TAA. Consequently,
the presence of CD4+ Melan-A-specific T-cells was in
general associated with poorer survival [18]. Similarly, in
breast cancer, survival was associated with a CD8+ T cell
response to Her-2 peptides and a negative role of both
MDSCs and Tregs was demonstrated in the prognosis of
these elderly breast cancer patients. The mechanism
might be through dampening favorable CD8+ T cell im-
mune responses to tumor-associated antigens [19].
In summary, functional responses of patient peripheral
blood to tumor antigens measured in vitro, as well as
surface marker phenotyping ex vivo, can predict survival
duration. Specificity of the response, nature of the
responding T cells and pro- or anti-inflammatory type of
response, as well as proportions and types of MDSCs,
are all important factors for patient survival in both mel-
anoma and breast cancer. Thus, immune monitoring of
peripheral blood identifies predictive biomarkers for pa-
tient survival and may provide insights into the mecha-
nisms involved in immune-mediated anti-cancer effects.
Counteracting immune suppression by modulation of
checkpoint blockade and inhibitors of CSF-R1
One of the methods used to improve adoptive T cell ther-
apy is the re-stimulation of the injected TIL (Tumor-
infiltrating lymphocyte) cells with tumor vaccine express-
ing same antigen as recognized by TILs to improve life-
span. In a phase I clinical trial Poschke et al. [20] com-
bined a dendritic cell (DC) vaccination and TIL infusion
in malignant melanoma. The treatment with the two cel-
lular products was found feasible and safe for the eight pa-
tients with stage IV melanoma enrolled in the trial.
Although the small study size precluded analysis of clin-
ical responses, one patient showed a complete remission
and two had stable disease. The analysis of T-cell receptor
repertoire in TIL by next-generation sequencing revealed
presence of highly dominant clones in most infusion
products which could, in the majority of cases, be detected
in the circulation by qPCR after T-cell transfer. Another
trial combining DC vaccination and adoptive T cell trans-
fer in a two-step approach in patients preconditioned with
non-myeloablative chemotherapy is ongoing (EUdrac-CT
#2012-000450-63).
Also, a combination of IFN-γ and multiple Toll-like
receptor agonists proved superior in activating DCs to
tumor-specific activation, thus permitting an improve-
ment of the quality of the DC vaccine. Even the possibil-
ity of combining adoptive T cell transfer with silencing
checkpoint molecules was explored. Antibodies repre-
sent one possibility, but another intriguing option is a
new technology by which the checkpoint molecules
could be directly silenced in the injected T cells.
Hydrophobically modified “self-deliverable” small RNA
(sdRNA) can effectively enter cells and results showed
that PD-1 silencing in healthy T cells by using sdRNA
leads to significant decrease in surface and as well
intracellular levels of PD-1 expression in TILs. Activated
PD-1 silenced healthy T cells and TILs produced more
IFN-γ upon tumor specific stimulation. In addition,
PD-1 silenced TILs proved enhanced capacity to kill
autologous tumor cells and, finally, the percentage of
CD45RA- CCR7- effector memory CD8+ and CD4+
TILs increased after PD-1 silencing. MDSCs are being
evaluated as a new target for cancer immunotherapy
and one of the unanswered questions is whether
checkpoint blockade mediate some of their effects by
targeting immune suppressive cells (Tregs, MDSCs,
macrophages) or their products. Anti-CTLA4 treatment
results in a strong reduction of immuno-suppressive cells
(GrMDSC, Tregs) and agents (Arginase, iNOS) in the
majority of treated patients [21].
Neuroblastoma is the most common extracranial solid
cancer type in childhood, and high-risk patients have poor
prognosis. Similar to malignant melanoma, neuroblastoma-
driven inflammation contributes to the induction of
suppressive myeloid cells that hamper efficient antitumor
immune responses. Infiltrating CSF-1R+ myeloid cells
predicted poor clinical outcome in patients with neuro-
blastoma (R2: microarray analysis and visualization
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platform [22]). In vitro, neuroblastoma-derived factors in-
terfered with early development of myeloid cells and en-
abled suppressive functions on human monocytes through
M-CSF/CSF-1R interaction [23]. In a transgenic mouse
model (TH-MYCN) resembling high-risk human neuro-
blastoma, antagonizing CSF-1R with a selective inhibitor
(BLZ945, Novartis) was found to modulate the induction of
human and murine suppressive myeloid cells and to effi-
ciently limit tumor progression. Checkpoint inhibitors as
monotherapy was found to be insufficient in controlling
tumor growth, while combining BLZ945 with PD-1/PD-L1
blocking antibodies resulted in superior tumor control.
Response and resistance to PD-1 pathway blockade: clues
from the tumor microenvironment
Monoclonal antibodies blocking anti-PD-1 immune
checkpoint showed an unprecedented spectrum of activ-
ity versus different cancer types providing a “common
denominator” for cancer therapy [24]. On this note, the
US food and drug administration (FDA) already ap-
proved their usage for the treatment of patients with
metastatic melanoma, advanced NSCLC, RCC and
Hodgkin’s lymphoma. Great attention is now focused on
identifying biomarkers able to predict response or resist-
ance to anti-PD-1 treatment [25]. It has been previously
identified that PD-L1 expression on the tumor cell sur-
face is one factor associated with the clinical activity of
anti–PD-1 [26]. Notably, a significant number of patients
with PD-L1+ expression still do not respond to PD-1
pathway blockade, suggesting that additional intratu-
moral factors may influence treatment outcomes.
In melanoma, by comparing PD-L1+ vs. PD-L1(−) tu-
mors, it has been shown an overexpression of genes in-
volved in CD8+ T-cell activation (e.g., CD8A, IFNG) and
immunosuppression pathways (e.g., PD-1, LAG3 and
IL10) in PD-L1+ tumors, thus suggesting the coordinate
expression of multiple immunological factors mediating
therapy response to anti PD-1 blockade [27]. However, a
deep molecular analysis performed on formalin-fixed,
paraffin-embedded (FFPE) pretreatment tumor biopsies
expressing PD-L1 (PD-L1+) and derived from patients
with RCC showed that none of the immune molecules
previously found to be significantly overexpressed in
PD-L1+ melanomas was associated with anti-PD-1 treat-
ment response. On the contrary, additional immunologic
factors and novel metabolic molecules were found to be
associated with treatment resistance in RCC. Particu-
larly, genes involved in metabolic and solute transport
functions, also found in kidney cancer cell lines, were
found associated with treatment failure of patients with
PD-L1+ RCC. Conversely tumors from responding pa-
tients overexpressed immune markers such as BACH2, a
regulator of CD4+ T cell differentiation, and CCL3 in-
volved in leukocyte migration [28]. Thus, the intratumoral
balance between metabolic and immunologic gene expres-
sion might determine the effective response to anti-PD-1
blockade in RCC. This is not surprising if we consider that
RCC has been characterized as a metabolic disease, with
the signature up-regulation of factors adapting to hypoxia
and functioning to meet the bioenergetic demands of cel-
lular proliferation [29]. These evidences suggested that the
general approach used to identifying markers predicting
clinical response to anti-PD-1-targeted therapies, which
has mostly focused on modulatory receptors and ligands
(e.g., PD-1, PD-L2, LAG-3) and T cell infiltrates, must be
revaluated. Indeed a deeper level of investigation might be
warranted for individual tumor types to which these new
therapies are being applied.
Understanding and combining CD137-targeted
immunotherapy
Hepatocellular carcinoma (HCC) is typically an
inflammation-associated cancer that can be immuno-
genic [30]. Association of hepatitis C and hepatitis B in-
fection with upregulation of PD-1 has been reported
[31, 32], but it is associated with poor outcomes [33].
Immune checkpoint inhibition (anti-CTLA-4) has
shown encouraging activity in an early clinical trial in
HCC [34] and also PD-1 blockade with nivolumab may
boost host immunity against HCC and improve clinical
outcomes. Preliminary data from a phase I/II study on
safety and antitumor activity of nivolumab show durable
though partial response and an OS rate at 6 months of
72 % [35].
CD137 is a surface glycoprotein involved in T cell co-
stimulation, with functions in T cell proliferation, inhib-
ition of apoptosis, cytotoxic activity enhancement and
cytokine production. Treatment with anti-CD137 agon-
ist monoclonal antibodies can overcome tumor antigen
tolerance [36]. On the other hand, mouse experimentation
provided both a rational and a recipe for immunotherapy
combinations: (1) procedures aimed at enhancing the
number of primed nonanergic T cells in the organism by
means of vaccines, adoptive transfer, or procedures to en-
hance the immunogenicity of a tumor lesion, and (2) strat-
egies to de-repress or stimulate artificially the ongoing
immune response, for the most part considering immu-
nostimulatory monoclonal antibodies [37]. Based on this,
co-infusion of both agonist antibodies and T cells has been
shown to attain marked synergistic effects that result from
more focused and intense cytolytic activity visualized
under in vivo microscopy and from more efficient en-
trance of T cells into the tumor through the vasculature.
These several levels of dynamic interaction between adop-
tive T cell therapy and CD137 offer much opportunity to
raise the efficacy of current cancer immunotherapies [38].
In particular, anti-CD137 infusion may enhance adoptive
immunotherapy by CTL by a dual mechanism, enhancing
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endogenous effector functions as well as focusing and
prolonging the efficacy of therapeutically transferred lym-
phocytes [39]. New studies, including cross-priming of
CD137 with DC and combination of immunostimulatory
monoclonal antibodies anti-hCD137 (urelumab) with
anti-hPD-1 (nivolumab) are presenting promising results.
Combination immunotherapy with autologous stem cell
transplantation, protein immunization, and PBMC
reinfusion in myeloma patients
Multiple myeloma is rich in tumor antigens of the
cancer-testis (CT) family conferring spontaneous im-
munogenicity, with CT7 (MAGE-C1) and MAGE-A3/6
already known to correlate with plasma-cell proliferation
[40] and with NY-ESO-1 eliciting spontaneous humoral
and T-cell immunity [41]. Antibody responses to CT an-
tigens were found after treatment with allogeneic stem
cell transplant in multiple myeloma patients, which
might help to achieve long-lasting remissions [42].
Autologous Stem Cell Transplant (ASCT) is a standard
of care for some multiple myeloma patients but not
curative. ASCT might be used as a platform for adoptive
immunotherapy, considering that myeloablative therapy
may provide immunologic benefits, such as tumor anti-
gen release for cross-presentation and priming,
lymphopenia-induced proliferation of T cells, and elim-
ination of suppressor populations (Tregs, MDSCs).
Nevertheless, ASCT also results in durable immunosup-
pression, as evidenced by frequent CMV reactivation.
Combining vaccination and ASCT was therefore investi-
gated for CT antigen MAGE-A3, taking into account po-
tential benefits and risks of MAGE-A3 targeting in
adoptive transfer, reported to lead to clinical tumor re-
gression in 5 out of 9 metastatic cancer patients (7 with
metastatic melanoma, 1 with synovial sarcoma, 1 with
esophageal cancer) but also neurological toxicity associ-
ated with lymphocytic brain infiltration, probably due to
cross-reactivity with an epitope from MAGE-A12
expressed in human brain [43]. A pilot study of MAGE-
A3 antigen-specific cancer immunotherapeutic (rec-
MAGE-A3 protein + AS15) as consolidation for multiple
myeloma patients undergoing ASCT has recently com-
pleted accrual, and was safe and well tolerated. Using
mass cytometry for phenotypic analysis of immune re-
constitution, preliminary results show an inversion of
CD4 / CD8 ratio and a B cell dip and rebound after
ASCT. Nevertheless, antigen-specific assays (ELISA,
ELISPOT, Intracellular cytokine staining) for MAGE-A3
showed induction of a strong antibody and Th1-biased
CD4 T cell response in all patients. In conclusion, a
combined approach of vaccination with ASCT is feasible
and overcomes typical immunosuppression in multiple
myeloma patients. Absence of MAGE-A expression ob-
served in some patients upon disease relapse suggests
potential immune selective pressure, and calls for com-
bination strategies to limit antigen escape.
Anti-cancer immunity despite T cell “exhaustion”
The three main stumbling blocks for anti-cancer T cells
are (1) low T cell numbers and low TCR affinity (with
ACT and vaccination as possible solutions), (2) ineffi-
cient priming/boosting (with checkpoint blockade or
vaccination as possible solutions), and (3) T cell suppres-
sion in the TME (with checkpoint blockade, radiation, or
intratumoral injection of “adjuvants” as possible solu-
tions) [44].
Tumor antigen specific T cells in the TME only pro-
duce low levels of cytokines, thus their effector functions
are relatively weak. For the first time in any species, the
Speiser group analyzed T cells from a TME by gene ex-
pression array [45], demonstrating that the molecular
profile significantly resembled the one of T cell “exhaus-
tion” that was first defined in chronic mouse and then
human infections [46]. During chronic infection, T cells
progressively lose their functional properties. T cell ex-
haustion is also accompanied by a progressive increase
in the amount and diversity of inhibitory receptors
expressed. Altered inflammation and changes in immu-
noregulatory cytokines can have important roles. Ultim-
ately, if the severity and/or duration of the infection is
high and/or prolonged, virus-specific T cells can be com-
pletely eliminated, leading to loss of protective T cell re-
sponses. The severity of T cell exhaustion correlates with
inhibitory receptor expression, viral (and antigen) load,
loss of CD4+ T cell help, and infection duration. Similar
observations were made for metastatic melanoma, the
disease studied by the group. They showed this by mo-
lecular profiling of CD8+ T cells not only in humans,
but also in an autochthonous mouse melanoma model,
finding several corresponding molecular hits [45, 47, 48].
They also demonstrated a remarkable coexistence of
fully functional effector cells in circulation and
exhausted cells in the tumor environment. An important
hit, i.e., a gene that was significantly overexpressed in
TIL was Maf, an AP-1 family member. Subsequent ex-
periments demonstrated that Maf is a first in-class driver
of exhaustion [47, 48], as Maf overexpression reproduces
and enhances a large number of molecular and func-
tional features of exhausted cells, and deletion of Maf re-
verses exhaustion as T cells become strongly functional
and eliminate cancers.
Another aspect studied by the group is that exhausted
cells still have some functional competence, indicating
that exhaustion is not an optimal term, T cell “dysfunc-
tion” might be better, or “long term effector T cell popu-
lation”, because these cells are heterogeneous and likely
contain short and (very) long lived cell subsets [49]. In
fact, absence of “exhausted” cells renders diseases worse,
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both in chronic infections and in various cancers. There-
fore, the group proposes that exhausted cells are special-
ized with respect to differentiation and activation,
adapted to the disease in which these T cells stably ad-
just their effector capacity to the conditions of chronic
infection or cancer. This phenotype is optimized to
cause minimal tissue damage while still mediating a crit-
ical level of pathogen control. This concept provides a
rationale for emerging therapies that enhance T cell ac-
tivity in chronic infection and cancer e.g., by blocking
inhibitory receptors [49]. Clearly, many dysfunctional
cells can regain function within short time, as revealed
by strong cytotoxicity by those T cells [50].
The group also studied T cell responses from
melanoma patients treated with the anti-CTLA-4 anti-
body Ipilimumab. Long-term observations suggest that
responder patients progressively had less Tregs in blood,
and particularly also in tumors. Furthermore, responders
had higher levels of non-classical CD16+ monocytes
compared with non responder patients. As CD16 binds
Ipilimumab, experiments were performed to determine
whether these CD16+ monocytes could mediate antibody-
dependent cell- mediated cytotoxicity (ADCC). Indeed,
this was the case, leading to specific killing of Tregs due
to their constitutive CTLA-4 expression at high levels
[51]. Another paper, a collaborative work performed in
the lab of Pia Kvistborg, Ton Schumacher et al., reports
the analysis of melanoma patients’ PBMC with an HLA-
A2 tetramer panel comprising 145 tumor antigens. The
study shows that anti–CTLA-4 treatment induced a sig-
nificant increase in the number of detectable CD8 T cell
specificities. Thus, the therapy induced considerable
broadening of the immune response, demonstrating that
Ipilimumab may not primarily act on effector cells but ra-
ther on other immune cells, likely Tregs and DCs that can
mobilize many novel T cell populations that help fighting
cancer [52]. Another paper describes that melanoma pa-
tients treated with ipilimumab experienced a significant
increase in the number of detectable CD8 T cell specific-
ities. Thus, the therapy induced considerable broadening
of the immune response, demonstrating that ipilimumab
may not primarily act on already activated effector T cells
but rather on other immune cells, likely Tregs and DCs
that can activate many novel T cell populations that help
fighting cancer [52]. This study was a collaborative work
performed in the lab of Pia Kvistborg, Ton Schumacher et
al., who developed and applied an HLA-A2 tetramer panel
detecting CD8 T cells with 145 different antigen
specificities.
Predictor of response to radiation and immunotherapy
An in vitro model recently showed that radiotherapy (RT)
produces both a radiation dose-dependent induction and
chemotherapeutic enhancement of immunogenic cell
death (ICD) as well as induction of ICD by the combin-
ation of radiation and certain chemotherapy agents [53].
These findings provide preliminary evidence that ICD
stimulated by either high-dose radiotherapy alone, or con-
current chemo-radiation regimens, may contribute to the
establishment of a peritumoral proimmunogenic milieu
[53]. In combination with different forms of immunother-
apy, RT stimulates the release of antigens and also the sig-
nals in the tumor microenvironment that allow T cells to
permeate the surviving tumor, and contribute to cell kill-
ing so that the tumor is converted into an in situ vaccine.
Since 2004, the combination of DC growth factors in
combination with RT were found to induce abscopal
effects in a syngeneic mouse model [54]. These findings
were translated to the clinic, where a combination of
radiotherapy with granulocyte-macrophage colony-
stimulating factor produced objective abscopal re-
sponses in 11 out of 41 patients with metastatic solid
tumors refractory to treatment [55]. The results of
this clinical trial also highlighted the importance of
role of host’s “immune integrity” in the process, with
more patients responding among those with a neutro-
phil to lymphocyte ratio <4. A similar translation of
preclinical to clinical results was demonstrated with a
combination of immune checkpoint blockade and
radiotherapy. In the 4 T1 syngeneic mouse model of
metastatic mammary carcinoma, it was shown that
RT to a peripheral tumor and CTLA-4 blockade
achieved both reduction of lung metastases and im-
proved survival compared either modality alone [56].
Consistently, in a patient with chemotherapy-
refractory metastatic adenocarcinoma of the lung, an
abscopal response was seen 2 ½months after the start
of treatment with ipilimumab and fractionated RT,
supporting the belief that a combination of RT and
immunotherapy might prove to be a useful strategy to
improve the outcomes of some cancer patients with
metastases that are historically known to have dismal
prognoses [57].
RT alone is seldom capable of inducing rejection of ag-
gressive poorly immunogenic tumors. RT ability to induce
tumor rejection is dependent on the balance of positive
and negative signals that pre-exist or are induced by RT it-
self. Barriers to the potential of radiation to convert a
tumor into an in situ vaccine might be associated with
classical immunosuppressive microenvironment of estab-
lished tumors or be RT-induced immunosuppressive ef-
fects. One of the immunosuppressive signals generated by
RT is the activation transforming growth factor (TGF) β
[58]. Because TGFβ regulates many processes that can
affect tumor growth, including angiogenesis, a compre-
hensive assessment of the major changes by gene expres-
sion analysis was performed. The top 500 genes selectively
upregulated in RT + TGF beta blockade treatment group
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were identified using the Pavlidis Template Matching
Method, defining a majority of genes involved in the im-
mune response. The concept was investigated in a trial of
RT with fresolimumab in metastatic breast cancer, that
failed to show responses with the combination. The role
of adaptive immune resistance was in limiting tumor re-
sponse to radiotherapy and TGFβ blockade was investi-
gated in a mouse model: increased PDL-1 and PDL-2
expression on tumor and myeloid cells was demonstrated,
compared to controls. PD-1 blockade extended survival
and delayed tumor recurrence in mice treated with radi-
ation and TGFβ blockade [59], suggesting that PD-1
blockade may be required to unleash the effect of combin-
ing TGFβ blockade and RT. In summary, results of RT
and immunotherapy combinations from preclinical exper-
iments in syngeneic models of different murine tumors
were consistently confirmed in the clinic. RT remains a
powerful adjuvant to multiple immunotherapy strategies.
Checkpoint inhibitors in metastatic non-small cell lung
cancer
With limited current options for the treatment of ad-
vanced NSCLC and phase III studies of vaccines that to
date have failed to meet their primary endpoint, great at-
tention is being paid to checkpoint inhibitors. A double-
blind, phase 2 randomized controlled trial in treatment-
naïve patients with advanced NSCLC, proved that
phased ipilimumab plus chemotherapy improved both
irPFS (immune-related PFS) and PFS. Overall rates of
grade 3 and 4 immune-related adverse events were 15 %
(control 6 %) [60]. Nivolumab monotherapy in a phase
II single arm trial found meaningful activity (15 % ORR)
and a manageable safety profile (17.1 % grade 3/4 ad-
verse events) in previously treated patients with ad-
vanced, refractory, squamous NSCLC [61]. Nivolumab
was tested versus chemotherapy in a multicenter, open-
label, phase III, randomized trial in previously-treated
patients with advanced or metastatic squamous NSCLC,
and overall survival (mOS 9.2 vs 6.0), response rate, and
progression-free survival were significantly better with
nivolumab, regardless of PD-L1 expression level [62].
The corresponding trial in metastatic non-squamous
NSCLC (multicenter, open-label, phase III, randomized
trial in previously-treated patients) was stopped earlier
due to efficacy and nivolumab was associated with even
greater efficacy (e.g., mOS 12.2 vs 9.4) than docetaxel
across all end points in subgroups defined according to
prespecified levels of tumor-membrane expression of the
PD-1 ligand. Treatment-related adverse events of grade
3 or 4 were reported in 10 % of patients in the nivolu-
mab group, as compared with 54 % of those in the doce-
taxel group [63].
The phase I study of pembrolizumab in monotherapy
in patients with advanced NSCLC, it had an acceptable
side-effect profile and showed antitumor activity in pa-
tients (median duration of response exceeds 1 year).
Also, PD-L1 expression in at least 50 % of tumor cells
correlated with improved efficacy of pembrolizumab
[64]. A multicenter, open-label, phase II/III, randomized
trial in previously-treated patients with PD-L1-positive
NSCLC, demonstrated that pembrolizumab prolongs
overall survival (mOS 10.4 with pembrolizumab 2 mg/kg,
12.7 with pembrolizumab 10 mg/kg, 8.5 with docetaxel)
and has a favorable benefit-to-risk profile in this selected
population [65]. In the multicenter, open-label, phase 3,
randomized trial in treatment-naïve patients with PD-L1+
advanced or metastatic NSCLC, pembrolizumab showed a
manageable safety profile and promising antitumor activ-
ity [66]. Preliminary data from a phase II trial of pembroli-
zumab in untreated brain metastases in NSCLC showed
antitumoral activity (33 % brain metastasis response rate)
and good tolerability [67]. In a multicenter, open-label,
phase II, randomized trial in previously-treated patients
with NSCLC, a pattern of improved survival that corre-
lates with PD-L1 expression and a good safety profile were
reported.
PD1/PDL1 Inhibition in metastatic renal cell carcinoma
The phase III study of nivolumab versus everolimus
demonstrated an overall survival benefit for patients
with advanced RCC treated with nivolumab, (mOS 25.0
vs 19.6) and was generally well tolerated with a low rate
of grade 3/4 events. Prespecified subgroup analyses did
not identify a population which did not benefit from
nivolumab in terms of overall survival (including pa-
tients with PD-L1 negative tumors). On the other hand,
a clinically meaningful and statistically significant im-
provement in quality of life was seen with nivolumab
versus everolimus for the duration of the study [68]. The
role of treatment beyond progression which was de-
scribed initially in a phase II dose ranging study in RCC,
is still being explored at this time since some patients
experience pseudoprogression on PD1 inhibition [69].
The dual immune checkpoint blockade with nivolumab
/ipilimumab therapy is showing an encouraging activity
with unprecedented ORR of about 40 % [70]. The com-
bination of nivolumab with the vascular endothelial
growth factor (VEGF) pathway inhibitors sunitinib or
pazopanib in mRCC has shown promising activity as
well, but was associated with significant liver toxicity
[71]. The association of immunotherapy with more se-
lective VEGF pathway inhibitors was investigated in a
phase Ib study with MPDL3280A and bevacizumab with
good safety and efficacy outcomes [72]. Phase II and III
trials combining immunotherapy and VEGF pathway in-
hibitors are currently ongoing and will most likely trans-
form first line therapy in the near future. However, a
number of questions (e.g., regarding who benefits the
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most, biomarkers availability, dosing schedule/cost
saving opportunities) still need to be answered.
Immune checkpoint inhibition for breast cancer
Breast cancer is the most common malignancy diag-
nosed in women worldwide. Approximately 15 % of
breast cancers are triple-negative. As triple-negative
breast cancers (TNBC) lack expression of ER, PR, and
HER2, they do not benefit from available targeted ther-
apies. TNBC is associated with a younger age at diagno-
sis, an advanced stage at diagnosis, and a worse clinical
outcome. The rationale for investigating immunotherapy
for TNBC comes from a number of observations made
over the past several years. For one, we know that ER
negative tumors have a higher density of tumor infiltrat-
ing lymphocytes (TILs) than ER positive tumors [73],
which can in turn facilitate and immune response.
Mittendorf and colleagues found that TNBCs have in-
creased PD-L1 expression, which can suppress T cell
function [74]. Gene expression profiling has revealed at
least six distinct subtypes of TNBC, including an immu-
nomodulatory subtype which is characterized by elevated
expression of genes involved in T cell function [75]. And
finally, the genomic instability and high mutation rates
in TNBCs can produce neoantigens that induce an
immune response [76]. Based on these observations, im-
mune checkpoint inhibition was studied in TNBC. The
phase Ib multi-cohort KEYNOTE-12 study enrolled
patients with PD-L1 positive TNBC. The 32 patients en-
rolled were treated with single-agent pembrolizumab at
10 mg/kg every 2 weeks, which demonstrated an accept-
able safety profile (events of a potentially immune-
mediated nature, regardless of attribution, included
pruritus, hepatitis, and hypothyroidism), and was associ-
ated with prolonged responses in 18.5 % of patients en-
rolled in the study [77]. Preliminary data from a phase Ia
study of the PD-L1 inhibitor atezolizumab demonstrated
a similar safety and tolerability profile, as well as early
signs of durable clinical activity with a RR of 19 % [78].
PD-1 or PD-L1 blockade in TNBC is associated with a
response rate approaching 20 %, and while somewhat
lower than the RR in melanoma (30-40 % range), is
comparable to monotherapy response rates in other
solid tumors. The responses are durable and immune
checkpoint inhibitors are safe and tolerable, with the
majority of side effects being mild and easily managed.
Future work is aimed at building on these promising
monotherapy responses with the combination of differ-
ent checkpoint inhibitors or with radio/chemo-therapy.
The role of immunotherapy in ovarian cancer
Despite advances in combinatorial chemotherapy regi-
mens, current therapeutic options for ovarian cancer
(OC) patients are inadequate and the majority of
patients will relapse and die of disease, with a 5-year sur-
vival of approximately 30 %. The strong presence of
TILs is strongly, positively associated with improved
survival, the activity of TILs (CD3+ and CD8+ cells) as
antitumor effectors and the identification of tumor-
associated antigens (TAAs) that up-regulate in tumor
tissue and ascites of OC patients (Her2/neu, Folate Re-
ceptor α, p53, CA125, members of the cancer-testis anti-
gen family like MAGE –A4 and NY-ESO-1), all account
for the evidence of OC immunogenicity.
The immunohistochemical analysis of frozen specimens
from advanced-stage ovarian carcinomas showed signifi-
cant differences in the distributions of progression-free sur-
vival and overall survival according to the presence or
absence of intratumoral T cells. Patients whose tumors
contained T cells had a median duration of progression-
free survival of 22.4 months and a median duration of over-
all survival of 50.3 months, as compared with 5.8 and
18.0 months, respectively, among patients whose tumors
did not contain T cells [79]. Later, intraepithelial CD8+
tumor-infiltrating lymphocytes and a high CD8+/regulatory
T cell ratio were found to be associated with favorable
prognosis in OC (mOS 55 vs 26 months) [80]. When tak-
ing into account selected published studies that evaluated
the association between TIL and patient survival, the prog-
nostic value of TILs persisted among populations with di-
verse histologic tumor subtypes, regardless of the stage or
grade of disease [81]. The Cancer Genome Atlas findings
on OC showed that there are few recurrent mutated genes,
with four transcript subtypes and the presence of extensive
defects homologous recombination with mutual exclusivity
[82]. Considering that BRCA 1/2 mutated OC are known
to be associated with improved survival and that the
presence of TILs (CD3+ and CD8+) and high CD8+/CD4+
ratio are associated with favorable OS in OC, a pilot study
explored the differences in the presence of TILs and PD-1
and PD-L1 expression between BRCA mutated and non
mutated. The results showed a significantly higher
CD8+/CD4+ ratio in BRCA1/2-mutated tumors and
peritumoral CD3+ T-cells significantly increased in
BRCA1/2-mutated compared to non-BRCA1/2-mutated
ovarian cancers. An elevated number of CD3+ and CD8+
in BRCA1/2-mutated OC may provide an additional ex-
planation for the improved clinical outcomes associated
with these mutations. In patients with platinum-resistant
OC receiving nivolumab, a phase II trial on a very limited
number of patients found that nivolumab at 1 mg/kg was
well tolerated and has encouraging clinical efficacy [83].
In a phase Ib, open-label expansion trial in patients
with previously treated, recurrent or refractory ovarian
cancer, avelumab demonstrated an acceptable safety pro-
file and to be clinically active [84]. Activity of avelumab
was higher in patients with platinum sensitive recur-
rence compared to the resistant and in patients with less
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line of previous chemotherapy. The interim results from a
phase Ib study with pembrolizumab in patients with PD-L1
positive advanced OC, has also demonstrated antitumor ac-
tivity in heavily pretreated patients and a manageable safety
and toxicity profile [85]. The first phase 2 and 3 trials are
ready to start also in ovarian cancer addressing the role of
immunotherapy in all treatment settings of the disease. In
the next future it will be also important to identify the
dominant immunosuppressive pathways in the different
OC subtypes that will allow patients to be optimally
matched with therapies. Also, combination strategies
should be explored with standard and emerging therapies.
Conclusions
Based on the characteristics of the immune system to
exhibit innate and adaptive responses to tumors and to
maintain a memory of such responses, the “modern” im-
munotherapy with checkpoint inhibitors got remarkable
results mainly in melanoma patients with the possibility
to reach long-term benefit. This results were translated
into different malignancies, and there are a lot of clinical
studies still ongoing. However, important results include
improvement in OS for NSCLC and RCC; these data
have already well established in clinical practice. More-
over, promising results have been also obtained in head
and neck, Hodgkin lymphoma, breast and ovarian can-
cer, neuroblastoma, and myeloma.
Data from ongoing clinical trials and further researches
will provide more information about mechanisms of acti-
vation and resistance, as well as combination approaches.
A critical issue will be also to provide biomarkers which
could be predictive of response.
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